Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Early research (Phase 1)Looking for participantsNCT05614739
What this trial is testing

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company 535
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Not applicableLooking for participantsNCT06410976
What this trial is testing

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 150
Testing effectiveness (Phase 2)Ended earlyNCT02952573
What this trial is testing

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Who this might be right for
Multiple MyelomaRelapsed/Refractory
University Health Network, Toronto 20
Testing effectiveness (Phase 2)Looking for participantsNCT04153422
What this trial is testing

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Who this might be right for
Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory Polyneuropathy+1 more
Endeavor Health 20
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+11 more
Tyra Biosciences, Inc 100
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05145010
What this trial is testing

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 300
Early research (Phase 1)Looking for participantsNCT06874335
What this trial is testing

BHV-1530 in Advanced Solid Tumors

Who this might be right for
Solid Tumor
Biohaven Therapeutics Ltd. 95
Testing effectiveness (Phase 2)Study completedNCT01058434
What this trial is testing

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Testing effectiveness (Phase 2)Study completedNCT04919642
What this trial is testing

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Who this might be right for
CholangiocarcinomaFGFR2 FusionFGFR2 Gene Mutation+2 more
TransThera Sciences (Nanjing), Inc. 55
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Not applicableStudy completedNCT00106977
What this trial is testing

Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)

Who this might be right for
CraniosynostosisMuenke Syndrome
National Human Genome Research Institute (NHGRI) 137
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Not applicableStudy completedNCT02539329
What this trial is testing

Characterization of Anti-FGFR3 Antibodies

Who this might be right for
Sensory Peripheral Neuropathy
Centre Hospitalier Universitaire de Saint Etienne 251
Early research (Phase 1)Study completedNCT02529553
What this trial is testing

LY3076226 in Participants With Advanced or Metastatic Cancer

Who this might be right for
Advanced CancerMetastatic Cancer
Eli Lilly and Company 25
Testing effectiveness (Phase 2)WithdrawnNCT04040725
What this trial is testing

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Who this might be right for
Bladder Cancer
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Load More Results